Through the implementation of the SciCord Informatics Platform, Pearl Therapeutics’ teams realized significant advantages:
In 2015, Pearl Therapeutics, later acquired by AstraZeneca, began its journey as a small company dedicated to developing innovative inhaled formulations. Confronted with resource constraints, Pearl prioritized enhancing laboratory throughput and implementing data trending and visualizations to inform development strategies.
SciCord was contacted based on a previously successful inhaled data management solution at GSK by SciCord’s founder.
The success of Pearl Therapeutics pivoted on a seamless regulatory filing process. The adoption of SciCord brought forth profound effects:
SciCord provides a platform for an entire research and development organization. In our experience, pharmaceutical labs often cobble multiple solutions together and unfortunately isolate data and unknowingly create headaches for an already overburdened IT group.
We extend our sincere appreciation to Shyamala Ivatury (Senior Director, IPD, PT&D, Pearl/Astra Zeneca) for their invaluable guidance and collaboration throughout this endeavor.
Formulated Solutions streamlined operations and reduced costs by of $360,000 per year
Read MoreWith SciCord LIMS/ELN, Pearl Therapeutics improved review process efficiency by over 30%
Read MoreFDA audit issues can cost millions of dollars - Aurobindo has relied on SciCord to avoid FDA issues twice
Read MoreReach out to Schedule a Meeting and get more information about how SciCord can fit into your lab
Don’t take our word for it.
We exceed our client’s demands everyday to make their research and discovery process simpler and more efficient.
This is by far the best value in science software (or anything else in science, really) that we’ve ever experienced. Other solutions in this price range had a fraction of the features, and those with the features cost 3x – 10x more. We’re very happy customers.
Josh Guyer,
Senior Pharmaceutical Scientist